The global Biosimilar Monoclonal Antibodies Market was valued at USD 14.92 billion in 2024 and is projected to grow from USD 17.35 billion in 2025 to USD 58.07 billion by 2033, registering a robust CAGR of 16.3% during the forecast period (2025–2033). The market is witnessing remarkable expansion as healthcare systems worldwide increasingly adopt cost-effective biologic alternatives to...